Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi (SNY) has released an update ... TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Sanofi is scheduled to report results for the third quarter on ... Dow Jones Newswires Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with ...

David Risinger has given his Buy rating due to a combination of factors that highlight Sanofi’s strategic maneuvers and financial prospects ... In another report released yesterday, Jefferies ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab ... will be presented in 23 abstracts at ...

Yet, the company’s plans to open financial centers in new and existing ... research report on SAP here >>>) Other noteworthy reports we are featuring today include Boston Scientific Corp. (BSX), ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ...